Intervacc expands the distribution agreement with Animalcare Group plc
The animal health company Intervacc has through the wholly owned subsidiary Nordvacc Läkemedel AB (Nordvacc) expanded the distribution agreement with Ecuphar NV, a wholly owned subsidiary of Animalcare Group plc, a European company Headquartered in the UK. The agreement gives Nordvacc exclusive rights to sell a growing and innovative portfolio of veterinary pharmaceutical products from Animalcare Group plc on the Swedish market.
“It is very gratifying that we now can increase the cooperation, after close to two years of business with Animalcare. We look forward to introducing several interesting products to the Swedish market. This is an important step in the strategy to broaden our animal health product portfolio in collaboration with strong partners” – says Andreas Andersson, CEO Intervacc AB
Since its inception in 1988, Animalcare Group plc has built up a reputable brand based on innovative, high quality products in the veterinary pharmaceutical market. In July 2017, the merger between Animalcare and Ecuphar NV was carried out and together they operate in 32 countries in Europe and a further 16 countries worldwide. The company is listed on the London Stock Exchange’s AIM list.
The agreement covers the sale of veterinary pharmaceutical products for Companion Animals, Production Animals and Equine. The first two products in the agreement will be introduced on the Swedish animal health market already during the current year.
For more information please contact:
Andreas Andersson, CEO
E-mail: email@example.com, Phone: +46-8-120 10 601
Zoltan Dobolyi, Product manager
E-mail: firstname.lastname@example.org, Phone: +46-8-449 46 53
This information is information that Intervacc AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above on August 28, 2019.
Intervacc AB (publ) is a company within the Biotechnology sector. The Company´s main area is to develop modern sub-unit vaccines against economically important bacterial infections, within animal health. The company´s vaccine candidates are based on several years of research at Karolinska Institutet and Swedish University of Agricultural Research where the foundation was laid for the company´s research and development work. The Intervacc share has been listed on the Nasdaq First North market since April 2017 with Eminova Fondkommission AB, email@example.com, +46 (0)8–684 211 00 as Certified Adviser.
Animalcare Group plc is a UK AIM listed veterinary sales and marketing organisation resulting from the merger of Animalcare and Ecuphar NV in July 2017. Animalcare operates in 32 countries in Europe and a further 16 countries worldwide. The company is focused on bringing new and innovative products to market through its own development pipeline, partnerships and via acquisition. www.animalcaregroup.co.uk
Contact information for Certified Adviser
Eminova Fondkommission AB
E-mail: firstname.lastname@example.org, Phone: +46 (0)8 – 684 211 00